Incyte Corporation, headquartered in Wilmington, Delaware, is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company specializes in a range of therapeutic areas, particularly in oncology and hematology, with a strong emphasis on JAK inhibitors, FGFR inhibitors, and KRAS inhibitors. Incyte is also engaged in developing immunomodulators and various combination therapies, leveraging biomarkers to enhance treatment efficacy and patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

686 Patents

#12 in Wilmington, DE

#13 in Delaware

#734 in US

#1,456 in the World

Wilmington, DE, United States of America

Incyte Corporation

Forward Citations = 10,431

390 inventors:

Wenqing Yao (223 out of 228 patents)

Andrew Paul Combs (115 out of 128 patents)

Liangxing Wu (114 out of 114 patents)

4. Yun-Long Li (89 out of 96 patents)

5. Jincong Zhuo (71 out of 76 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Incyte Corporation. Retrieved from https://idiyas.com/company/incyte

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

35 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

96 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]